Plus Therapeutics, Inc. (PSTV)
Plus Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Plus Therapeutics, Inc. (PSTV) is a Biotechnology company based in US with a market capitalization of $9.3M. Revenue declined 10.5% year-over-year and free cash flow was negative at -$20.8M. This page tracks PSTV's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 21 employees · IPO Jul 11, 2001
Valuation
Valuation & price
$5.25as of May 17, 2026· -76.4% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
2.32
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$9.3M
Market cap
-10.5%
Revenue growth (YoY)
91.5%
Gross margin
-$20.8M
Free cash flow (USD)
-$7.9M
Net debt
Net cash position
1071.7%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2022 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last reported: May 15, 2026 (EPS $-1.05)
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- FinancingJun 5, 2026Filing
Securities Registration
- 8-K eventJun 5, 2026Filing
Equity Distribution Agreement
- FinancingJun 2, 2026Filing
Securities Registration
- 8-K eventMay 15, 2026Filing
Earnings Release
- Quarterly reportMay 15, 2026Filing
10-Q Filed
- 8-K eventMay 15, 2026Filing
Annual Meeting Results
- 8-K eventApr 21, 2026Filing
Regained Nasdaq Compliance
- 8-K eventApr 9, 2026Filing
Executive Employment Agreement
- 8-K eventApr 8, 2026Filing
Orphan Drug Designation
- 8-K eventApr 2, 2026Filing
Reverse Stock Split
Questions
Frequently asked questions
What is Plus Therapeutics, Inc.'s market cap?
Plus Therapeutics, Inc. (PSTV) has a market capitalization of $9.3M.
What is PSTV's P/E ratio?
A meaningful P/E ratio is not available for PSTV — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is PSTV's price-to-book (P/B) ratio?
PSTV trades at 2.32 times book value per share.
When did Plus Therapeutics, Inc. last report earnings?
PSTV last reported earnings on May 15, 2026; the next date is not yet scheduled.
Are insiders buying PSTV stock?
SEC Form 4 filings show no open-market insider buys at Plus Therapeutics, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.